Prof. Armin Gerger provides a review of the BEACON Study.
Prof. Armin Gerger provides a review of the BEACON Study.
Since 2012 Dr Armin Gerger is professor at the Medial University in Graz, Austria. He works as a clinical oncologist and coordinates the Subcentre for Gastrointestinal Neoplasia at the Comprehensive Cancer Centre, Graz. He leads the Pharmacogenetics Research Unit, at the Division of Clinical Oncology of the Medical University of Graz, and the Area “Cancer” of the Centre for Biomarker Research in Medicine (CBmed). Dr Gerger’s research focuses on prognostic and predictive genetic biomarkers in gastrointestinal cancer, which he developed further as a research fellow at the Norris Comprehensive Cancer Centre of the University of Southern California. Dr Gerger’s research activity is mirrored in several papers in high-ranked scientific journals and significant extramural funding.
An overview of the EMERALD subgroup analyses
A medical oncologist and a pathologist share their perspectives on best practices in identifying HER2-directed NSCLC
Survey findings presented at ONS 2025 and published in the journal Healthcare
What to know, what to expect, and where to find support
Optimising 1st and 2nd line treatment
Optimising precision medicine for improved patient outcomes